Form 10-Q Kymera Therapeutics, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Truist Securities 'Incrementally Positive' on Kymera Therapeutics (KYMR) Following Q1 Update
May 9, 2025 1:57 PM EDTTruist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $53.00 price target on Kymera Therapeutics (NASDAQ: KYMR) following Q1 results.
The analyst commented, "We are incrementally positive on KYMR following today's 1Q25 business update showcasing KT-579, an oral, selective degrader of... More
